Michael Weller

Michael Weller, MD is Chair of the Department of Neurology at University Hospital Zurich and Professor of Neurology at the University of Zurich. He is a leading European neuro-oncologist recognized internationally for his work on molecular biomarkers in glioma—especially MGMT promoter methylation—and for leading pivotal clinical trials in high-grade glioma. His laboratory and clinical research programs have been instrumental in delineating the molecular taxonomy of gliomas and translating biomarker discoveries into clinical practice. Dr. Weller has led or co-led numerous landmark EORTC trials in glioma, including the phase III NOA-08 and CeTeG/NOA-09 trials. The CeTeG/NOA-09 trial demonstrated that CCNU plus temozolomide conferred a significant overall survival benefit compared to temozolomide alone in patients with newly diagnosed, MGMT-methylated GBM, leading to widespread adoption of this regimen for this molecular subgroup. He has served as chair of the EORTC Brain Tumor Group and plays a central role in shaping European clinical trial infrastructure and guideline development through EANO. His translational research encompasses glioma immunology, the tumor microenvironment, and resistance mechanisms to both chemotherapy and immunotherapy. Dr. Weller has authored or co-authored over 500 peer-reviewed publications and is among the most highly cited investigators in neuro-oncology. He serves on the editorial boards of major neuro-oncology journals and has mentored a wide network of European neuro-oncology investigators.